Medifast (MED) Q1 2025: Active Coach Count Falls 33%, New Cohorts Signal Potential Inflection
Medifast’s first quarter saw a sharp contraction in its active coach base, but early signals from new coach cohorts and product innovation suggest the business is adapting to the GLP-1 disruption. Management is refocusing on its coach-led model and product mix, betting that these levers will stabilize client acquisition and set the stage for a turnaround in 2026. Investors should watch for sustained improvements in coach productivity and new client growth as leading indicators of a true inflection.
Summary
- Coach-Led Model Rebuilds: Medifast doubled down on empowering coaches to drive customer acquisition and retention.
- GLP-1 Adaptation Accelerates: New products and training target clients on or off weight loss medications.
- Inflection Efforts Underway: Early gains in new coach cohorts and productivity are crucial for a 2026 recovery.
Performance Analysis
Medifast’s Q1 2025 results reflected continued pressure on its core business model, with revenue declining sharply and the active earning OPTAVIA coach base dropping 33 percent year over year. This contraction was primarily attributed to ongoing competitive and behavioral shifts in the weight loss market, particularly the widespread adoption of GLP-1 medications, GLP-1, a class of weight loss drugs that suppress appetite and impact muscle mass.
Despite these headwinds, the company saw a notable moderation in productivity decline per coach, with revenue per coach down only 1.4 percent versus a 22 percent drop last year. New coach cohorts exhibited customer growth rates reminiscent of Medifast’s historic expansion periods, supported by targeted promotions and an evolving training approach. Gross margin remained robust at 72.8 percent, but fixed cost deleverage and increased company-led marketing spend pressured SG&A as a percentage of revenue. Net loss for the quarter reflected the lower sales base, partially offset by aggressive cost management.
- Coach Base Contraction: The active coach count fell to approximately 25,400, a decline that continues to weigh on topline results.
- Productivity Stabilization: New coach productivity is at levels seen during prior growth cycles, providing a potential foundation for future recovery.
- Product Mix Evolution: The Ascend product line, tailored for GLP-1 users, accounted for mid-teens percentage of orders and is performing in line with expectations.
While the business remains under pressure, the stabilization of key productivity metrics and the emergence of new coach cohorts are the most important signals for investors tracking the turnaround thesis.
Executive Commentary
"In 2025, we are sharpening our focus on reigniting that engine. We're taking action to help simplify the coaching experience, increase productivity, and create scalable and successful businesses through stronger new customer acquisition, better retention, and the re-engagement of former customers."
Dan Chard, Chairman and Chief Executive Officer
"Average revenue per active earning OPTAVIA coach for the first quarter was $4,556, a year-over-year decrease of 1.4% compared to a year-over-year decrease of 22.2% during Q1 of 2024. This moderation is being driven in part by increased productivity of newer coach cohorts, which are exhibiting new customer growth ahead of last year."
Jim Maloney, Chief Financial Officer
Strategic Positioning
1. Coach-Led Acquisition Engine
Medifast is doubling down on its core differentiator: the OPTAVIA coach network. Leadership is streamlining the coach development path, introducing more intuitive incentives, and investing in leadership education and digital business tools. Coach support is positioned as both the primary acquisition lever and the most efficient scaling mechanism. The company’s focus is on simplifying the coaching journey and amplifying early wins to drive new customer and coach acquisition.
2. GLP-1 Integration and Product Innovation
The rapid adoption of GLP-1 medications has forced Medifast to adapt its program and product portfolio. The company’s OPTAVIA Ascend line, specifically designed for GLP-1 users or those transitioning off the drugs, now represents a mid-teens share of orders. Nearly half of OPTAVIA coaches have supported GLP-1 clients, and a quarter have personal experience with the drugs, deepening the network’s relevance for this fast-growing segment. New studies are underway to validate the efficacy of both the Ascend and Essential lines, aiming to reinforce the scientific credibility of the holistic OPTAVIA model.
3. Marketing Mix Reset and Cost Focus
Medifast is pulling back on company-led marketing in favor of coach-driven acquisition, reallocating resources to initiatives with superior customer acquisition cost profiles. While company-led efforts will continue for customer reactivation, the bulk of investment is shifting to the coach community. Cost discipline is evident in SG&A reductions, but fixed cost deleverage remains a challenge at lower sales volumes.
4. Early Signs of Inflection
The first meaningful year-over-year increase in new coaches in three years is a critical data point, even if it has not yet translated into revenue growth. Management is explicit that improvement in new coach cohorts and productivity historically precedes broader business recovery, suggesting a potential inflection point if these trends persist into the back half of 2025 and 2026.
Key Considerations
Medifast’s strategic reset is centered on adapting to a fundamentally changed weight loss market, with GLP-1 drugs disrupting traditional behavior and acquisition channels. The company’s response is to double down on what it sees as its unique value: coach-led, holistic, science-backed programs that address both medicated and non-medicated weight loss journeys.
Key Considerations:
- Coach Productivity as Leading Indicator: The stabilization and growth of new coach productivity is the most important metric for forecasting a turnaround.
- GLP-1 Disruption Creates Opportunity: Medifast’s ability to serve GLP-1 users and “off-ramp” clients positions it to address a growing and complex segment.
- Product Innovation Pipeline: New product launches and ongoing clinical studies are designed to reinforce differentiation and address evolving customer needs.
- Cost Structure Flexibility: Aggressive SG&A management is helping preserve financial flexibility, but fixed cost deleverage will remain a challenge at lower volumes.
Risks
Medifast faces elevated execution risk as it pivots its business model in the face of a shrinking coach base and the disruptive impact of GLP-1 medications on consumer behavior. Sustained declines in coach count or failure to translate new cohort momentum into broader growth could delay or derail the turnaround. Additionally, competitive responses, regulatory changes to weight loss drugs, or further shifts in consumer preferences could add volatility and uncertainty to the recovery timeline.
Forward Outlook
For Q2 2025, Medifast guided to:
- Revenue of $85 million to $105 million
- Loss per share of $0.00 to $0.55
For full-year 2025, management did not provide formal guidance but highlighted:
- Expectations for improvement in coach productivity in the second half of 2025
- Potential for coach growth in the second half of 2026 if current trends hold
Management cited the importance of tracking new coach cohort performance, continued cost discipline, and the evolving impact of GLP-1 drugs on both customer and coach behavior as the primary variables shaping the outlook.
Takeaways
Medifast’s Q1 2025 results underscore the scale of the challenge posed by GLP-1 disruption, but also reveal early signs of strategic adaptation.
- Coach Network Is Central to Recovery: The company’s fate hinges on its ability to reignite coach-led acquisition and retention, with new cohort productivity as the key leading indicator.
- GLP-1 Market Is a Double-Edged Sword: While initially a headwind, the company is positioning itself to serve both users and non-users, with product and training investments targeting this segment.
- Inflection Timeline Is Elongated: Investors should expect continued volatility, with the first real signs of a turnaround likely not materializing until late 2025 or 2026 if current trends persist.
Conclusion
Medifast is navigating a profound business model transition, with coach network revitalization and GLP-1 integration at the core of its strategy. While the active coach base and topline remain under pressure, stabilization in new coach productivity and product innovation offer a plausible path to recovery. The next several quarters are critical for validating whether these early signals can translate into sustained growth.
Industry Read-Through
The GLP-1 disruption is reshaping the entire weight loss and wellness industry, forcing legacy players to evolve their offerings and go-to-market models. Medifast’s experience highlights the need for integrated, science-backed, and coach-supported solutions that address both medicated and non-medicated weight loss journeys. The company’s rapid pivot to support GLP-1 users, invest in new product lines, and retrain its field force is a blueprint for adaptation that other direct selling and wellness brands may need to follow. Expect continued shakeout among business models overly reliant on traditional diet paradigms, with future winners likely to be those who can bridge the gap between medical interventions and long-term lifestyle change.